
Evidation
Founded Year
2012Stage
Series E | AliveTotal Raised
$259.18MValuation
$0000Last Raised
$153M | 4 yrs agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-37 points in the past 30 days
About Evidation
Evidation focuses on harnessing real-world health data to measure and improve health outcomes. The company offers a digital health measurement and engagement platform that utilizes data science and machine learning to provide health guidance, treatments, and tools. Evidation primarily serves life sciences companies, government bodies, and academic institutions. It was founded in 2012 and is based in San Mateo, California.
Loading...
ESPs containing Evidation
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The real-world data providers market offers a variety of value propositions to the pharmaceutical industry, drug labs, and healthcare organizations. It provides access to diverse patient populations, longitudinal real-world data, and patient-powered or EHR-powered controls that can replicate real-world scenarios. This can help shorten drug development timelines, reduce patient recruitment burdens …
Evidation named as Outperformer among 15 other companies, including IQVIA, Tempus, and Datavant.
Evidation's Products & Differentiators
Research
Evidation runs programs for enterprises to get actionable evidence in three areas: disease burden and patient impact, patient segmentation and identification, disease event and progression modelling. We deploy a proven approach, incorporating our experience with over 200 research programs, to reliably delivers results. Given our connectivity with highly engaged individuals, we deliver faster and more cost-effectively.
Loading...
Research containing Evidation
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Evidation in 6 CB Insights research briefs, most recently on Aug 21, 2024.
Expert Collections containing Evidation
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Evidation is included in 6 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,270 items
Digital Health 50
300 items
The most promising digital health startups transforming the healthcare industry
Value-Based Care & Population Health
1,261 items
The VBC & Population Health collection includes companies that enable and deliver care models that address the health needs for defining populations along the continuum of care, including in the community setting, through participation, engagement, and targeted interventions.
Digital Health
11,306 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Telehealth
3,114 items
Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.
Precision Medicine Tech Market Map
160 items
This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.
Evidation Patents
Evidation has filed 12 patents.
The 3 most popular patent topics include:
- wearable devices
- machine learning
- epidemiology

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
10/18/2022 | 11/12/2024 | Smartwatches, Wearable devices, Wearable computers, Activity trackers, Health informatics | Grant |
Application Date | 10/18/2022 |
---|---|
Grant Date | 11/12/2024 |
Title | |
Related Topics | Smartwatches, Wearable devices, Wearable computers, Activity trackers, Health informatics |
Status | Grant |
Latest Evidation News
Mar 6, 2025
As President and COO, Wilberforce led Evidation's strategy and key partnerships across global pharma, technology, and public health organizations Evidation, the leader in direct-to-participant real-world data and health research, today announced the appointment of Leslie Oley Wilberforce as Chief Executive Officer. Wilberforce succeeds Christine Lemke, who will continue as an advisor and Board Member. A proven operator, strategic product leader, and seasoned dealmaker, Wilberforce has been instrumental in shaping Evidation's trajectory as a market leader in health research. As President and Chief Operating Officer, Wilberforce scaled the company's programs, teams, and market impact. She led the creation of Evidation's enterprise product and technology platform, and forged partnerships and programs with companies and organizations including The Michael J. Fox Foundation and The American Heart Association, connecting millions of individuals to groundbreaking health research. She also played a key role in Evidation's collaboration on the Heartline Study™ with Johnson & Johnson and Apple. Now, Wilberforce will lead Evidation into a pivotal new phase, focused on engaging cohorts of individuals directly and at scale to generate patient-centric, real-world data and insights with unprecedented speed and depth. With its AI-enabled technology, Evidation is uniquely positioned to transform how real-world data is collected and applied across healthcare. “Since I joined Evidation in 2015, we have pursued a fundamental shift in health research — one where individuals control their health data and can meaningfully and easily contribute their experience to real-world evidence generation,” said Wilberforce. “We've built a powerful, interactive technology platform that millions of people use to share their permissioned health data. I am honored and energized to lead Evidation at this moment — one where we can rapidly deliver deep and differentiated real-world insights from cohorts of individuals across therapeutic areas.” Wilberforce, a mechanical engineer by training, led product strategy and commercialization efforts at Boston Scientific, ApniCure, and Voyage Medical, focusing on data-driven health technology solutions, before joining Evidation. “Leslie is a driven leader whose operational prowess and people-first leadership approach have made her an indispensable force behind Evidation's success and the right leader for this moment,” said Christine Lemke, outgoing CEO and Co-founder of Evidation. “She has played a defining role in our growth, and I have full confidence she'll propel Evidation to deliver even greater impact in the years ahead.” Lemke's leadership shaped Evidation from the ground up, transforming a bold idea into a company that now serves millions of individuals globally. Along with former Co-CEO and Board Chair Deb Kilpatrick, she helped steer Evidation through multiple funding rounds, scaled operations, and cemented its place as a pioneer in real-world data and direct-to-participant research. About Evidation Evidation creates new ways to measure and improve health in everyday life—making proactive, personalized, and truly human-centered healthcare possible. By connecting directly with millions of individuals, Evidation harnesses real-world data to deeply understand health experiences, rapidly and at scale. Evidation's privacy-centric digital health measurement and engagement platform uses data science and machine learning to translate these everyday insights into high-impact health guidance, treatments, and tools. Founded in 2012, Evidation is headquartered in California, with employees working globally. Learn more at www.evidation.com View source version on businesswire.com: https://www.businesswire.com/news/home/20250306360045/en/ Contacts Media contact Greg Bowyer press@evidation.com
Evidation Frequently Asked Questions (FAQ)
When was Evidation founded?
Evidation was founded in 2012.
Where is Evidation's headquarters?
Evidation's headquarters is located at 63 Bovet Road, San Mateo.
What is Evidation's latest funding round?
Evidation's latest funding round is Series E.
How much did Evidation raise?
Evidation raised a total of $259.18M.
Who are the investors of Evidation?
Investors of Evidation include B Capital, McKesson Ventures, Kaiser Permanente Ventures, OMERS Private Equity, SV Health Investors and 12 more.
Who are Evidation's competitors?
Competitors of Evidation include Aetion, ObvioHealth, Tempus, Science 37, Money Walk and 7 more.
What products does Evidation offer?
Evidation's products include Research.
Loading...
Compare Evidation to Competitors

Medable specializes in providing digital clinical trial software solutions within the healthcare and pharmaceutical sectors. The company offers a comprehensive platform that facilitates the management of clinical trials, including tools for remote data collection, electronic consent (eConsent), patient-reported outcomes (ePRO), and clinical outcome assessments (eCOA), all designed to streamline the trial process and enhance data quality. Medable was formerly known as Dermatrap. It was founded in 2012 and is based in Palo Alto, California.

ObvioHealth provides digital health solutions within the clinical trial industry. The company has a platform and mobile application allows for remote monitoring and participation in clinical trials, focusing on data collection and participant engagement. ObvioHealth's services are relevant to the healthcare sector, especially in trial management. It was founded in 2017 and is based in New York, New York.

Castor operates within the healthcare sector and provides a clinical trial platform designed for the design, deployment, patient engagement, data collection, and analysis of clinical trials. The platform is adaptable and can meet the requirements of different stakeholders in the clinical research process. It primarily serves the healthcare sector. The company was founded in 2012 and is based in Amsterdam, Netherlands.

Owkin is an AI biotechnology company that employs artificial intelligence to improve drug discovery and development in the biopharmaceutical sector. The company specializes in AI-based identification of new treatments, clinical trial optimization, and diagnostic tool creation, while ensuring patient privacy through federated learning techniques. Owkin serves the biopharma and academic research communities. It was founded in 2016 and is based in New York, New York.

Curebase provides a range of software tools designed for clinical trial recruitment, consent, and data collection processes. Curebase primarily serves the clinical research industry, including CROs, research sites, and study participants. The company was founded in 2017 and is based in San Francisco, California.

Aetion provides real-world evidence solutions within the healthcare sector. The company offers software and services that analyze real-world data to provide insights on the safety, effectiveness, and value of medical treatments and technologies. Its clientele includes biopharma companies and government agencies to inform health care decisions and guide product development. It was founded in 2013 and is based in New York, New York.
Loading...